SLDB — Solid Biosciences Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1707502 ·
Last close
$6.23
Market Cap
$695.33M
52W High
$11.45
52W Low
$4.24
ADV30
1,355,095
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -57,655,000 -53,948,000 389,905,000 125,971,000 47,794,000
Jun 2026 0 — -57,384,000 -54,799,000 420,580,000 159,394,000 46,505,000
Mar 2026 0 — -57,308,000 -56,737,000 422,893,000 297,099,000 48,761,000
Dec 2025 0 — -49,403,000 -49,787,000 232,540,000 59,900,000 52,530,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-198,918,000
Investing CF
$-45,579,000
Financing CF
$308,526,000
CapEx
$-1,378,000
Dividends Paid
—
Buybacks
$-13,644,000
EPS Diluted TTM
$-1.74
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,123,259,000
Inventory
—
Receivables
—
ST Investments
$222,957,000
EBIT TTM
$-214,887,000
Pretax Income TTM
$-215,271,000
Interest Exp TTM
$60,000
Analysts
14

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -179,206,000 -174,325,000 232,540,000 52,530,000 180,010,000 -156,289,000
Dec 2024 0 -129,728,000 -124,697,000 188,662,000 51,416,000 137,246,000 -100,012,000
Dec 2023 0 -104,315,000 -96,015,000 164,939,000 38,458,000 126,481,000 -94,180,000
Dec 2022 8,094,000 -99,274,000 -85,981,000 260,252,000 48,586,000 211,666,000 -97,977,000

TTM Snapshot

Revenues TTM
$9,923,000
NetIncome TTM
$-207,099,000
OpCashFlow TTM
—
Assets (Latest)
$420,580,000
Forward EPS
$-1.61

Max Pain — expiry 2026-12-18

max pain strike: $7.00 · spot: $6.35 · call oi: 1,848 · put oi: 20

Peers — same industry

TickerNameMarket CapLastDaily %
ATTO Attovia Therapeutics, Inc. $679.29M $14.86 —
IAM Iambic Therapeutics, Inc. $674.04M $14.22 —
AURA Aura Biosciences, Inc. $744.13M $7.15 —
DBVT DBV Technologies S.A. $627.78M $9.99 —
GLUE Monte Rosa Therapeutics, Inc. $775.03M $9.07 —

News headlines (Yahoo Finance, 1h cache)

Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
2026-11-17 06:12 · Yahoo
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-11-10 13:08 · Yahoo
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-05 13:00 · Yahoo
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-04 21:07 · Yahoo
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
2026-10-26 12:00 · Yahoo
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
2026-10-20 12:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.